ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on August 9
CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 10, 2007--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceuticals company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, invites investors, journalists and the general public to listen to a live webcast of the Company's investment community meeting on August 9, 2007. The webcast will begin at 8:30 am ET and may be accessed through the investor relations section of the Company's website, www.immunogen.com. The meeting is expected to last approximately three hours, including a short break. An archive of the webcast will be available on the Company's website through August 23, 2007.
The meeting will include a discussion of ImmunoGen's TAP technology, product pipeline, and strategy for growth. It also will include a discussion of the Company's financial results for its fourth quarter and 2007 fiscal year. These results will be reported before the start of the meeting on August 9.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development.
CONTACT:
Investors:
Carol Hausner
Executive Director, Investor Relations and Corporate Communications
ImmunoGen, Inc.
(617) 995-2500
info@immunogen.com
Media:
Kathryn Morris
KMorrisPR
(845) 635-9828
Kathryn@kmorrispr.com
